Mobile

Open label, randomized, multicenter study to investigate the efficacy and safety of once-weekly (reduced administration frequency) NeoRecormon® (Epoetin beta) therapy versus thrice weekly NeoRecormon®...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-002119-28

Open label, randomized, multicenter study to investigate the efficacy and safety of once-weekly (reduced administration frequency) NeoRecormon® (Epoetin beta) therapy versus thrice weekly NeoRecormon® therapy in anemic patients with metastatic solid tumors receiving chemotherapy (or scheduled to receive chemotherapy)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To demonstrate that epoetin beta (NeoRecormon®) administered 30,000 IU once weekly (q1w) subcutaneously (sc) is at least as efficacious as epoetin beta (NeoRecormon®) administered 10,000 IU sc thrice weekly (tiw)

Critère d'inclusion

  • Anaemia in breast tumour subjects

Liens